Federation Bio Administers First Dose in Phase 1 Clinical Trial
- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...
Federation Bio Administers First Dose in Phase 1 Clinical Trial
Escient Pharmaceuticals Announces $120 Million Series C Financing
Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide
Neumora Therapeutics Announces $112 Million Series B Financing
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE
Gritstone Announces Updated Overall Survival Results in CRC Patients from Phase 1/2 Study of GRANITE
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing